Given that ARID1A sustains cell proliferation in response to DNA damage and cancer cells lacking ARID1A are potentially vulnerable to cisplatin (27), we next tried to unravel potential clinical significance of KMT2D in management of HCC. This evidence concerns the gene ARID1A and hepatocellular carcinoma.